Table 1. Clinical characteristics of 210 patients who underwent autologous peripheral blood stem cell transplantation.

|  |  |
| --- | --- |
| **Patient characteristics** | **Number (%)** |
| Total | 210 (100%) |
| Age, years – Median (range)  Age Groups  18-29  30-39  40-49  50-59  ≥ 60 | 43 (19-65)  51 (24.3%)  34 (16.2%)  45 (21.4%)  57 (27.1%)  23 (11.0%) |
| Gender  Male  female | 87 (41.4 %)  123 (58.6 %) |
| Underlying disease  Lymphoma  Multiple myeloma | 115 (54.8 %)  95 (45.2 %) |
| Disease status before transplant  Complete remission  Partial remission  Stable disease  unknown | 34 (16.1 %)  147 (70.0 %)  4 (2.0 %)  25 (11.9 %) |
| CMV status before transplant  IgG positive  IgM positive | 205 (97.6%)  10 (4.8 %) |
| CMV prophylaxis given  Acyclovir  Valacyclovir  Unknown | 198 (94.3%)  11 (5.2%)  1 (0.5%) |
| Conditioning regimen  Lymphoma patients  BEAM  TEAM  Multiple myeloma patients  Melphalan | 111 (96.5%)  4 (3.5%)  95 (100%) |
| Median time to engraftment, days (range)  Median neutrophil engraftment  Median platelet engraftment | 10 (7-15)  16 (7-47) |
| Mortality  Overall  Day 100 | 50 (23.8%)  6 (2.9%) |

Abbreviations: CMV, Cytomegalovirus; BEAM, BCNU, Etoposide, Cytarabine, Melphalan; TEAM, Thiotepa, Etoposide, Cytarabine, Melphalan